Pharmaceutical Manufacturing and Formulation Supply

The contract involves the manufacture and supply of Latanoprost Ophthalmic Solution at a concentration of 0.005% in 2.5 mL containers, adhering strictly to FDA regulations, current Good Manufacturing Practices, and military packaging standards to ensure safety, efficacy, and compatibility with Defense Department logistics. The product is intended for use by military medical personnel and must meet rigorous quality and documentation requirements consistent with federal pharmaceutical procurement protocols. Production and packaging must be executed within a certified facility capable of maintaining sterility and consistency across all batches, with full traceability and compliance documentation required for inspection and audit readiness. The solicitation, issued under the NAICS code 325412 for Pharmaceutical Preparation Manufacturing, is structured as a subcontract within the Department of Defense’s Medical Supply Chain Pharmaceutical FSA framework and is tied to performance at Fort Bragg, North Carolina, with a zip code of 28310. The opportunity was posted on May 11, 2026, and responses are due by May 18, 2026, indicating a tight turnaround for qualified manufacturers to submit proposals. While no set-aside designation is specified, the contract is part of a broader federal effort to secure reliable, domestic sources of critical ophthalmic pharmaceuticals for military healthcare systems, emphasizing the need for proven capability, compliance, and on-time delivery under high-stakes operational conditions.